AI
ByIs Ignota Labs Turning Pharma’s Failed Assets into a New AI-Driven Value Class?
Strategic Overview Ignota Labs is taking a fundamentally different approach to AI in biopharma—one that focuses not on…
Is XtalPi Emerging as Pharma’s AI Engine for Molecular Property Prediction and Manufacturability at Scale?
Strategic Overview XtalPi is carving out a differentiated position in the AI-biopharma landscape by focusing on one of…
Is Owkin Building the Clinical Data Intelligence Layer as Pharma Commits Over $1.5 Billion to Federated AI Partnerships?
Strategic Overview Owkin is positioning itself at the center of a critical bottleneck in drug development: access to…
Is Isomorphic Labs Becoming Pharma’s Foundational AI Platform as Partnerships Surpass $3 Billion and Alphabet Commits $600 Million?
Strategic Overview Isomorphic Labs is emerging as one of the most structurally important AI companies in drug discovery—less…
Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…
Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?
January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…
